血栓性血小板减少性紫癜的显著多样性:一种观点
获得性血栓性血小板减少性紫癜(TTP)的自身免疫病因学认识提升了诊断精准性并支持免疫抑制治疗,也使患者初发表现和长期结局的显著临床多样性得以被认识。来自俄克拉荷马TTP登记处的患者故事展示了这些多样性,包括无症状严重血小板减少、治疗前猝死、ADAMTS13活性报告正常或意外缺乏等情形。由于TTP不常见,指导治疗变化的数据很少,患者的经历成为决策的重要依据。
要点
- 获得性TTP的自身免疫病因学认识为诊断提供了精准性并支持免疫抑制治疗。
- TTP初发表现多样,可仅为无症状的意外严重血小板减少,也可在治疗前猝死。
- 临床缓解期ADAMTS13活性不可预测,可恢复正常、持续严重缺乏或多年后才恢复。
核心结论
- 对获得性TTP自身免疫病因的认识提升了诊断精准性并支持免疫抑制治疗,也使患者初发表现和长期结局的显著临床多样性得以被认识。
- 由于TTP不常见,指导治疗变化的数据很少,患者的经历成为决策的重要依据。
研究设计与样本
- 本文为观点类文章,基于俄克拉荷马TTP登记处患者的经历进行阐述。
主要发现
- TTP初发表现可为症状轻微或无症者的意外严重血小板减少,患者可在整个治疗期间无症状,或尚未开始治疗即猝死。
- 具有TTP典型临床特征的患者ADAMTS13活性可报告为正常,而另一已确诊疾病患者意外报告ADAMTS13缺乏可导致TTP被发现。
- 临床缓解期ADAMTS13活性不可预测,可恢复并保持正常、持续严重缺乏多年,或恢复多年后才转为正常。
- 在急性发作治疗中加入利妥昔单抗,以及对缓解期严重ADAMTS13缺乏患者进行抢先利妥昔单抗治疗,据报道可预防复发。
临床怎么用
- 对初发发作的治疗以及患者恢复后和缓解期间的管理仍在不断变化。
- 急性发作治疗中加入利妥昔单抗,以及对缓解期严重ADAMTS13缺乏患者进行抢先利妥昔单抗治疗,据报道可预防复发。
局限性
- 由于TTP不常见,指导这些治疗变化的数据很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding the autoimmune etiology of acquired thrombotic thrombocytopenic purpura (TTP) has provided precision for the diagnosis and a rationale for immunosuppressive treatment. These advances have also allowed recognition of the remarkable clinical diversities of patients' initial presentations and their long-term outcomes. These diversities are illustrated by the stories of patients from the Oklahoma TTP Registry. The initial presentation of TTP may be the discovery of unexpected severe thrombocytopenia in a patient with minimal or no symptoms. The patient may remain asymptomatic throughout treatment or may die suddenly before treatment can be started. ADAMTS13 activity may be reported as normal in a patient with characteristic clinical features of TTP, or the unexpected report of ADAMTS13 deficiency in a patient with another established disorder may lead to the discovery of TTP. ADAMTS13 activity during clinical remission is unpredictable. ADAMTS13 activity may recover and remain normal, it may remain severely deficient for many years, or it may become normal only many years after recovery. Our treatment of initial episodes and management of patients after recovery and during remission continue to change. The addition of rituximab to the treatment of acute episodes and preemptive rituximab for patients with severe ADAMTS13 deficiency during remission are reported to prevent relapse. Because TTP is uncommon, there are few data to guide these changes. Therefore our patients' stories are profoundly influential. Their stories are the foundation of our experience, and our experience is the guide for our decisions.
引用
- George JN. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. Blood Adv. 2018. PMID: 29945940. doi:10.1182/bloodadvances.2018018432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。